Effects of the modulation of microbiota on the gastrointestinal immune system and bowel function

Journal of Agricultural and Food Chemistry

Volumn 61, Issue 42, 2013, Pages 9977-9983

  Kanauchi, Osamu ^a   Andoh, Akira ^b   Mitsuyama, Keiichi ^c  

^a KIRIN HOLDINGS CO LTD   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

cognition; dietary fiber; dysfunction; inflammation; inflammatory bowel disease; irritable bowel syndrome; microbiota; serotonin; short chain fatty acids; stress

Indexed keywords

FATTY ACIDS; METABOLITES; PATHOLOGY; PROBIOTICS; STRESSES;

COGNITION; DIETARY FIBERS; DYSFUNCTION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; IRRITABLE BOWEL SYNDROMES; MICROBIOTAS; SEROTONIN; SHORT-CHAIN FATTY ACIDS;

IMMUNE SYSTEM;

PROBIOTIC AGENT;

ANIMAL; BACTERIUM; GASTROINTESTINAL TRACT; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; METABOLISM; MICROBIOLOGY; MICROFLORA; REVIEW;

ANIMALS; BACTERIA; GASTROINTESTINAL TRACT; HUMANS; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASES; MICROBIOTA; PROBIOTICS;

EID: 84886459794     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf402441f     Document Type: Review

References (88)

1. Hawrelak, J. A.; Myers, S. P. The causes of intestinal dysbiosis: a review Altern. Med. Rev. 2004, 9, 180-197
2. Guarner, F. The intestinal flora in inflammatory bowel disease: normal or abnormal? Curr. Opin. Gastroenterol. 2005, 21, 414-418
3. Neish, A. S. Microbes in gastrointestinal health and disease Gastroenterology 2009, 136, 65-80
4. Andoh, A.; Kuzuoka, H.; Tsujikawa, T.; Nakamura, S.; Hirai, F.; Suzuki, Y.; Matsui, T.; Fujiyama, Y.; Matsumoto, T. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease J. Gastroenterol. 2012, 47, 1298-1307
5. The-Human-Microbiome-Project-Consortium: structure, function and diversity of the healthy human microbiome. Nature 2012, 486, 207-214.
6. Cho, I.; Blaser, M. J. The human microbiome: at the interface of health and disease Nat. Rev. Genet. 2012, 13, 260-270
7. Yatsunenko, T.; Rey, F. E.; Manary, M. J.; Trehan, I.; Dominguez-Bello, M. G.; Contreras, M.; Magris, M.; Hidalgo, G.; Baldassano, R. N.; Anokhin, A. P.; Heath, A. C.; Warner, B.; Reeder, J.; Kuczynski, J.; Caporaso, J. G.; Lozupone, C. A.; Lauber, C.; Clemente, J. C.; Knights, D.; Knight, R.; Gordon, J. I. Human gut microbiome viewed across age and geography Nature 2012, 486, 222-227
8. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K. S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T.; Mende, D. R.; Li, J.; Xu, J.; Li, S.; Li, D.; Cao, J.; Wang, B.; Liang, H.; Zheng, H.; Xie, Y.; Tap, J.; Lepage, P.; Bertalan, M.; Batto, J. M.; Hansen, T.; Le Paslier, D.; Linneberg, A.; Nielsen, H. B.; Pelletier, E.; Renault, P.; Sicheritz-Ponten, T.; Turner, K.; Zhu, H.; Yu, C.; Li, S.; Jian, M.; Zhou, Y.; Li, Y.; Zhang, X.; Li, S.; Qin, N.; Yang, H.; Wang, J.; Brunak, S.; Dore, J.; Guarner, F.; Kristiansen, K.; Pedersen, O.; Parkhill, J.; Weissenbach, J.; Bork, P.; Ehrlich, S. D.; Wang, J. A human gut microbial gene catalogue established by metagenomic sequencing Nature 2010, 464, 59-65
9. Kau, A. L.; Ahern, P. P.; Griffin, N. W.; Goodman, A. L.; Gordon, J. I. Human nutrition, the gut microbiome and the immune system Nature 2011, 474, 327-336
10. Klement, E.; Lysy, J.; Hoshen, M.; Avitan, M.; Goldin, E.; Israeli, E. Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study Am. J. Gastroenterol. 2008, 103, 1775-1782
11. Gwee, K. A. Irritable bowel syndrome in developing countries-a disorder of civilization or colonization? Neurogastroenterol. Motil. 2005, 17, 317-324
12. Andoh, A.; Imaeda, H.; Aomatsu, T.; Inatomi, O.; Bamba, S.; Sasaki, M.; Saito, Y.; Tsujikawa, T.; Fujiyama, Y. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis J. Gastroenterol. 2011, 46, 479-486
13. Spiller, R. Review article: probiotics and prebiotics in irritable bowel syndrome Aliment. Pharmacol. Ther. 2008, 28, 385-396
14. Spiller, R.; Lam, C. The shifting interface between IBS and IBD Curr. Opin. Pharmacol. 2011, 11, 586-592
15. Elinav, E.; Strowig, T.; Kau, A. L.; Henao-Mejia, J.; Thaiss, C. A.; Booth, C. J.; Peaper, D. R.; Bertin, J.; Eisenbarth, S. C.; Gordon, J. I.; Flavell, R. A. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis Cell 2011, 145, 745-757
16. Erridge, C.; Duncan, S. H.; Bereswill, S.; Heimesaat, M. M. The induction of colitis and ileitis in mice is associated with marked increases in intestinal concentrations of stimulants of TLRs 2, 4, and 5 PLoS One 2010, 5, e9125
17. Gionchetti, P.; Rizzello, F.; Campieri, M. Probiotics and antibiotics in inflammatory bowel disease Curr. Opin. Gastroenterol. 2001, 17, 331-335
18. Schultz, M.; Sartor, R. B. Probiotics and inflammatory bowel diseases Am. J. Gastroenterol. 2000, 95, S19-S21
19. Cryan, J. F.; O'Mahony, S. M. The microbiome-gut-brain axis: from bowel to behavior Neurogastroenterol. Motil. 2011, 23, 187-192
20. Kashyap, P. C.; Marcobal, A.; Ursell, L. K.; Larauche, M.; Duboc, H.; Earle, K. A.; Sonnenburg, E. D.; Ferreyra, J. A.; Higginbottom, S. K.; Million, M.; Tache, Y.; Pasricha, P. J.; Knight, R.; Farrugia, G.; Sonnenburg, J. L. Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice Gastroenterology 2013, 144, 967-977
21. Shanahan, F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288, G417-G421
22. Kanauchi, O.; Matsumoto, Y.; Matsumura, M.; Fukuoka, M.; Bamba, T. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease Curr. Pharm. Des. 2005, 11, 1047-1053
23. Venturi, A.; Gionchetti, P.; Rizzello, F.; Johansson, R.; Zucconi, E.; Brigidi, P.; Matteuzzi, D.; Campieri, M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis Aliment. Pharmacol. Ther. 1999, 13, 1103-1108
24. Sanders, M. E.; Guarner, F.; Guerrant, R.; Holt, P. R.; Quigley, E. M.; Sartor, R. B.; Sherman, P. M.; Mayer, E. A. An update on the use and investigation of probiotics in health and disease Gut 2012, 62, 787-796
25. Kruis, W.; Fric, P.; Pokrotnieks, J.; Lukas, M.; Fixa, B.; Kascak, M.; Kamm, M. A.; Weismueller, J.; Beglinger, C.; Stolte, M.; Wolff, C.; Schulze, J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine Gut 2004, 53, 1617-1623
26. Butterworth, A. D.; Thomas, A. G.; Akobeng, A. K. Probiotics for induction of remission in Crohn's disease Cochrane Database Syst. Rev. 2008, CD006634
27. Naidoo, K.; Gordon, M.; Fagbemi, A. O.; Thomas, A. G.; Akobeng, A. K. Probiotics for maintenance of remission in ulcerative colitis Cochrane Database Syst. Rev. 2011, CD007443
28. Macfarlane, S.; Macfarlane, G. T.; Cummings, J. H. Review article: prebiotics in the gastrointestinal tract Aliment. Pharmacol. Ther. 2006, 24, 701-714
29. Fukuda, M.; Komiyama, Y.; Mitsuyama, K.; Andoh, A.; Aoyama, T.; Matsumoto, Y.; Kanauchi, O. Prebiotic treatment reduced preneoplastic lesions through the downregulation of toll like receptor 4 in a chemo-induced carcinogenic model J. Clin. Biochem. Nutr. 2011, 49, 57-61
30. Manichanh, C.; Rigottier-Gois, L.; Bonnaud, E.; Gloux, K.; Pelletier, E.; Frangeul, L.; Nalin, R.; Jarrin, C.; Chardon, P.; Marteau, P.; Roca, J.; Dore, J. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach Gut 2006, 55, 205-211
31. Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermudez-Humaran, L. G.; Gratadoux, J. J.; Blugeon, S.; Bridonneau, C.; Furet, J. P.; Corthier, G.; Grangette, C.; Vasquez, N.; Pochart, P.; Trugnan, G.; Thomas, G.; Blottiere, H. M.; Dore, J.; Marteau, P.; Seksik, P.; Langella, P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 16731-16736
32. Vogt, L.; Ramasamy, U.; Meyer, D.; Pullens, G.; Venema, K.; Faas, M. M.; Schols, H. A.; de Vos, P. Immune modulation by different types of β2→1-fructans is toll-like receptor dependent PLoS One 2013, 8, e68367
33. Brower, V. Nutraceuticals: poised for a healthy slice of the healthcare market? Nat. Biotechnol. 1998, 16, 728-731
34. Brower, V. A nutraceutical a day may keep the doctor away. Consumers are turning increasingly to food supplements to improve well-being when pharmaceuticals fail EMBO Rep. 2005, 6, 708-711
35. Kanauchi, O.; Mitsuyama, K.; Andoh, A. The therapeutic impact of manipulating microbiota in inflammatory bowel disease Curr. Pharm. Des. 2009, 15, 2074-2086
36. Hamilton, M. J.; Snapper, S. B.; Blumberg, R. S. Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance J. Gastroenterol. 2012, 47, 1-8
37. Wada, S.; Sato, K.; Ohta, R.; Wada, E.; Bou, Y.; Fujiwara, M.; Kiyono, T.; Park, E. Y.; Aoi, W.; Takagi, T.; Naito, Y.; Yoshikawa, T. Ingestion of low dose pyroglutamyl leucine improves dextran sulfate sodium-induced colitis and intestinal microbiota in mice J. Agric. Food Chem. 2013, 8807-8813
38. Faure, M.; Mettraux, C.; Moennoz, D.; Godin, J. P.; Vuichoud, J.; Rochat, F.; Breuille, D.; Obled, C.; Corthesy-Theulaz, I. Specific amino acids increase mucin synthesis and microbiota in dextran sulfate sodium-treated rats J. Nutr. 2006, 136, 1558-1564
39. Gionchetti, P.; Rizzello, F.; Lammers, K. M.; Morselli, C.; Tambasco, R.; Campieri, M. Antimicrobials in the management of inflammatory bowel disease Digestion 2006, 73 (Suppl. 1) 77-85
40. Prantera, C.; Zannoni, F.; Scribano, M. L.; Berto, E.; Andreoli, A.; Kohn, A.; Luzi, C. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin Am. J. Gastroenterol. 1996, 91, 328-332
41. Rutgeerts, P.; Hiele, M.; Geboes, K.; Peeters, M.; Penninckx, F.; Aerts, R.; Kerremans, R. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection Gastroenterology 1995, 108, 1617-1621
42. Bouin, M.; Plourde, V.; Boivin, M.; Riberdy, M.; Lupien, F.; Laganiere, M.; Verrier, P.; Poitras, P. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds Gastroenterology 2002, 122, 1771-1777
43. Oufir, L. E.; Barry, J. L.; Flourie, B.; Cherbut, C.; Cloarec, D.; Bornet, F.; Galmiche, J. P. Relationships between transit time in man and in vitro fermentation of dietary fiber by fecal bacteria Eur. J. Clin. Nutr. 2000, 54, 603-609
44. Torii, A.; Toda, G. Management of irritable bowel syndrome Intern. Med. 2004, 43, 353-359
45. Spiller, R. Serotonergic agents and the irritable bowel syndrome: what goes wrong? Curr. Opin. Pharmacol. 2008, 8, 709-714
46. Lupp, C.; Robertson, M. L.; Wickham, M. E.; Sekirov, I.; Champion, O. L.; Gaynor, E. C.; Finlay, B. B. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae Cell Host Microbe 2007, 2, 204
47. Simren, M.; Barbara, G.; Flint, H. J.; Spiegel, B. M.; Spiller, R. C.; Vanner, S.; Verdu, E. F.; Whorwell, P. J.; Zoetendal, E. G. Intestinal microbiota in functional bowel disorders: a Rome Foundation Report Gut 2013, 62, 159-176
48. Takahashi, T.; Nakade, Y.; Fukuda, H.; Tsukamoto, K.; Mantyh, C.; Pappas, T. N. Daily intake of high dietary fiber slows accelerated colonic transit induced by restrain stress in rats Dig. Dis. Sci. 2008, 53, 1271-1277
49. Coates, M. D.; Mahoney, C. R.; Linden, D. R.; Sampson, J. E.; Chen, J.; Blaszyk, H.; Crowell, M. D.; Sharkey, K. A.; Gershon, M. D.; Mawe, G. M.; Moses, P. L. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome Gastroenterology 2004, 126, 1657-1664
50. Kassinen, A.; Krogius-Kurikka, L.; Makivuokko, H.; Rinttila, T.; Paulin, L.; Corander, J.; Malinen, E.; Apajalahti, J.; Palva, A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects Gastroenterology 2007, 133, 24-33
51. Ohman, L.; Simren, M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 163-173
52. Lizko, N. N. Stress and intestinal microflora Nahrung 1987, 31, 443-447
53. Saulnier, D. M.; Ringel, Y.; Heyman, M. B.; Foster, J. A.; Bercik, P.; Shulman, R. J.; Versalovic, J.; Verdu, E.; Dinan, T. G.; Hecht, G. A.; Guarner, F. The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes 2013, 4, 17-27.
54. Larauche, M.; Mulak, A.; Yuan, P. Q.; Kanauchi, O.; Tache, Y. Stress-induced visceral analgesia assessed non-invasively in rats is enhanced by prebiotic diet World J. Gastroenterol. 2012, 18, 225-236
55. Forsythe, P.; Kunze, W. A.; Bienenstock, J. On communication between gut microbes and the brain Curr. Opin. Gastroenterol. 2012, 28, 557-562
56. Rupa, P.; Mine, Y. Recent advances in the role of probiotics in human inflammation and gut health J. Agric. Food Chem. 2012, 60, 8249-8256
57. Ait-Belgnaoui, A.; Han, W.; Lamine, F.; Eutamene, H.; Fioramonti, J.; Bueno, L.; Theodorou, V. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction Gut 2006, 55, 1090-1094
58. Kanauchi, O.; Mitsuyama, K.; Komiyama, Y.; Yagi, M.; Andoh, A.; Sata, M. Preventive effects of enzyme-treated rice fiber in a restraint stress-induced irritable bowel syndrome model Int. J. Mol. Med. 2010, 25, 547-555
59. Madden, J. A.; Hunter, J. O. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics Br. J. Nutr. 2002, 88 (Suppl. 1) S67-S72
60. Thibault, R.; De Coppet, P.; Daly, K.; Bourreille, A.; Cuff, M.; Bonnet, C.; Mosnier, J. F.; Galmiche, J. P.; Shirazi-Beechey, S.; Segain, J. P. Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation Gastroenterology 2007, 133, 1916-1927
61. Komiyama, Y.; Andoh, A.; Fujiwara, D.; Ohmae, H.; Araki, Y.; Fujiyama, Y.; Mitsuyama, K.; Kanauchi, O. New prebiotics from rice bran ameliorate inflammation in murine colitis models through the modulation of intestinal homeostasis and the mucosal immune system Scand. J. Gastroenterol. 2011, 46, 40-52
62. Whelan, K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews Curr. Opin. Clin. Nutr. Metab. Care 2011, 14, 581-587
63. Kajander, K.; Myllyluoma, E.; Rajilic-Stojanovic, M.; Kyronpalo, S.; Rasmussen, M.; Jarvenpaa, S.; Zoetendal, E. G.; de Vos, W. M.; Vapaatalo, H.; Korpela, R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota Aliment. Pharmacol. Ther. 2008, 27, 48-57
64. Ritchie, M. L.; Romanuk, T. N. A meta-analysis of probiotic efficacy for gastrointestinal diseases PLoS One 2012, 7, e34938
65. Akihisa, T.; Ogihara, J.; Kato, J.; Yasukawa, K.; Ukiya, M.; Yamanouchi, S.; Oishi, K. Inhibitory effects of triterpenoids and sterols on human immunodeficiency virus-1 reverse transcriptase Lipids 2001, 36, 507-512
66. Kuhbacher, T.; Ott, S. J.; Helwig, U.; Mimura, T.; Rizzello, F.; Kleessen, B.; Gionchetti, P.; Blaut, M.; Campieri, M.; Folsch, U. R.; Kamm, M. A.; Schreiber, S. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis Gut 2006, 55, 833-841
67. Kanauchi, O.; Serizawa, I.; Araki, Y.; Suzuki, A.; Andoh, A.; Fujiyama, Y.; Mitsuyama, K.; Takaki, K.; Toyonaga, A.; Sata, M.; Bamba, T. Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment J. Gastroenterol. 2003, 38, 134-141
68. Totsuka, T.; Kanai, T.; Nemoto, Y.; Tomita, T.; Tsuchiya, K.; Sakamoto, N.; Okamoto, R.; Watanabe, M. Immunosenescent colitogenic CD4(+) T cells convert to regulatory cells and suppress colitis Eur. J. Immunol. 2008, 38, 1275-1286
69. Ostanin, D. V.; Pavlick, K. P.; Bharwani, S.; D'Souza, D.; Furr, K. L.; Brown, C. M.; Grisham, M. B. T cell-induced inflammation of the small and large intestine in immunodeficient mice Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G109-G119
70. Mowat, A. M. Anatomical basis of tolerance and immunity to intestinal antigens Nat. Rev. Immunol. 2003, 3, 331-341
71. Russo, G. L.; Della Pietra, V.; Mercurio, C.; Palumbo, R.; Iacomino, G.; Russo, M.; Tosto, M.; Zappia, V. Protective effects of butyric acid in colon cancer Adv. Exp. Med. Biol. 1999, 472, 131-147
72. Kovarik, J. J.; Tillinger, W.; Hofer, J.; Holzl, M. A.; Heinzl, H.; Saemann, M. D.; Zlabinger, G. J. Impaired anti-inflammatory efficacy of n -butyrate in patients with IBD Eur. J. Clin. Invest. 2011, 41, 291-298
73. Bocker, U.; Yezerskyy, O.; Feick, P.; Manigold, T.; Panja, A.; Kalina, U.; Herweck, F.; Rossol, S.; Singer, M. V. Responsiveness of intestinal epithelial cell lines to lipopolysaccharide is correlated with Toll-like receptor 4 but not Toll-like receptor 2 or CD14 expression Int. J. Colorectal Dis. 2003, 18, 25-32
74. Fukata, M.; Michelsen, K. S.; Eri, R.; Thomas, L. S.; Hu, B.; Lukasek, K.; Nast, C. C.; Lechago, J.; Xu, R.; Naiki, Y.; Soliman, A.; Arditi, M.; Abreu, M. T. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288, G1055-G1065
75. McBurney, M. I. Potential water-holding capacity and short-chain fatty acid production from purified fiber sources in a fecal incubation system Nutrition 1991, 7, 421-424
76. Barbara, G.; Stanghellini, V.; Brandi, G.; Cremon, C.; Di Nardo, G.; De Giorgio, R.; Corinaldesi, R. Interactions between commensal bacteria and gut sensorimotor function in health and disease Am. J. Gastroenterol. 2005, 100, 2560-2568
77. Wedlake, L.; A'Hern, R.; Russell, D.; Thomas, K.; Walters, J. R.; Andreyev, H. J. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome Aliment. Pharmacol. Ther. 2009, 30, 707-717
78. Pimentel, M.; Lin, H. C.; Enayati, P.; van den Burg, B.; Lee, H. R.; Chen, J. H.; Park, S.; Kong, Y.; Conklin, J. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G1089-G1095
79. Verdu, E. F.; Bercik, P.; Verma-Gandhu, M.; Huang, X. X.; Blennerhassett, P.; Jackson, W.; Mao, Y.; Wang, L.; Rochat, F.; Collins, S. M. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice Gut 2006, 55, 182-190
80. Rousseaux, C.; Thuru, X.; Gelot, A.; Barnich, N.; Neut, C.; Dubuquoy, L.; Dubuquoy, C.; Merour, E.; Geboes, K.; Chamaillard, M.; Ouwehand, A.; Leyer, G.; Carcano, D.; Colombel, J. F.; Ardid, D.; Desreumaux, P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors Nat. Med. 2007, 13, 35-37
81. Akiho, H.; Ihara, E.; Nakamura, K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome World J. Gastrointest. Pathophysiol. 2010, 1, 97-105
82. Spiller, R. Serotonin and GI clinical disorders Neuropharmacology 2008, 55, 1072-1080
83. Bercik, P.; Wang, L.; Verdu, E. F.; Mao, Y. K.; Blennerhassett, P.; Khan, W. I.; Kean, I.; Tougas, G.; Collins, S. M. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction Gastroenterology 2004, 127, 179-187
84. Langhorst, J.; Junge, A.; Rueffer, A.; Wehkamp, J.; Foell, D.; Michalsen, A.; Musial, F.; Dobos, G. J. Elevated human β-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome Am. J. Gastroenterol. 2009, 104, 404-410
85. Ohman, L.; Isaksson, S.; Lundgren, A.; Simren, M.; Sjovall, H. A controlled study of colonic immune activity and β7+ blood T lymphocytes in patients with irritable bowel syndrome Clin. Gastroenterol. Hepatol. 2005, 3, 980-986
86. Bercik, P.; Verdu, E. F.; Collins, S. M. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol. Clin. North Am. 2005, 34, 235-245 (vi-vii)
87. Robles Alonso, V.; Guarner, F. Linking the gut microbiota to human health Br. J. Nutr. 2013, 109 (Suppl. 2) S21-26
88. Sommer, F.; Backhed, F. The gut microbiota-masters of host development and physiology Nat. Rev. Microbiol. 2013, 11, 227-238